Sustiva is a brand name of efavirenz, approved by the FDA in the following formulation(s):
SUSTIVA (efavirenz - capsule; oral)
Manufacturer: BRISTOL MYERS SQUIBB
Approval date: September 17, 1998
Strength(s): 200MG [RLD], 50MG
SUSTIVA (efavirenz - tablet; oral)
Manufacturer: BRISTOL MYERS SQUIBB
Approval date: February 1, 2002
Strength(s): 600MG [RLD]
Has a generic version of Sustiva been approved?
No. There is currently no therapeutically equivalent version of Sustiva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sustiva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Benzoxazinones as inhibitors of HIV reverse transcriptase
Patent 5,519,021
Issued: May 21, 1996
Inventor(s): Young; Steven D. & Britcher; Susan F. & Payne; Linda S. & Tran; Lekhanh O. & Lumma, Jr.; William C.
Assignee(s): Merck & Co., Inc.
Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Patent expiration dates:
- May 21, 2013✓✓
- May 21, 2013
- May 21, 2013
Benzoxazinones as inhibitors of HIV reverse transcriptase
Patent 5,663,169
Issued: September 2, 1997
Inventor(s): Young; Steven D. & Payne; Linda S. & Britcher; Susan F. & Tran; Lekhanh O. & Lumma, Jr.; William C.
Assignee(s): Merck & Co., Inc.
Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable saks, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Patent expiration dates:
- September 2, 2014✓
- September 2, 2014
- September 2, 2014✓
- September 2, 2014
Benzoxazinones as inhibitors of HIV reverse transcriptase
Patent 5,811,423
Issued: September 22, 1998
Inventor(s): Young; Steven D. & Payne; Linda S. & Britcher; Susan F. & Tran; Lekhanh O. & Lumma, Jr.; William C.
Assignee(s): Merck & Co., Inc.
Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Patent expiration dates:
- August 7, 2012✓✓✓
- August 7, 2012✓
- August 7, 2012
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
Patent 6,238,695
Issued: May 29, 2001
Inventor(s): Makooi-Morehead; William T. & Buehler; John D. & Landmann; Brian R.
Assignee(s): DuPont Pharmaceuticals Company
The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.Patent expiration dates:
- April 6, 2019✓
- April 6, 2019
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
Patent 6,555,133
Issued: April 29, 2003
Inventor(s): William T.; Makooi-Morehead & John D.; Buehler & Brian R.; Landmann
Assignee(s): Bristol-Myers Squibb Company
The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.Patent expiration dates:
- April 6, 2019✓
- April 6, 2019
Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Patent 6,639,071
Issued: October 28, 2003
Inventor(s): Louis S.; Crocker & Joseph L.; Kukura, II & Andrew S.; Thompson & Christine; Stelmach & Steven D.; Young
Assignee(s): Merck & Co., Inc.
The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.Patent expiration dates:
- February 14, 2018✓
- February 14, 2018
Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
Patent 6,939,964
Issued: September 6, 2005
Inventor(s): Crocker; Louis S. & Kukura, II; Joseph L. & Thompson; Andrew S. & Stelmach; Christine & Young; Steven D.
Assignee(s): Merck & Co., Inc.
The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.Patent expiration dates:
- January 20, 2018✓
- January 20, 2018
See also...
- Sustiva Consumer Information (Drugs.com)
- Sustiva Consumer Information (Wolters Kluwer)
- Sustiva Consumer Information (Cerner Multum)
- Sustiva Advanced Consumer Information (Micromedex)
- Sustiva AHFS DI Monographs (ASHP)
- Efavirenz Consumer Information (Wolters Kluwer)
- Efavirenz Consumer Information (Cerner Multum)
- Efavirenz Advanced Consumer Information (Micromedex)
- Efavirenz AHFS DI Monographs (ASHP)
No comments:
Post a Comment